Page last updated: 2024-11-04

proadifen

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Proadifen, also known as SK&F 9157, is a non-competitive inhibitor of cholinesterase, an enzyme that plays a crucial role in nerve impulse transmission. It was synthesized in the 1950s and studied for its potential therapeutic use as a muscle relaxant and anticonvulsant. However, its clinical development was discontinued due to significant side effects. Proadifen was also investigated for its potential to enhance the effects of other drugs, such as opioids and anticholinergics, but these studies were ultimately unsuccessful. Despite its limited clinical application, proadifen remains a valuable tool for researchers studying cholinesterase inhibition and its impact on the nervous system. It has been used in various research settings to investigate the role of cholinesterase in neurodegenerative diseases, muscle disorders, and other conditions. The compound's mechanism of action, which involves binding to the active site of cholinesterase without competing with acetylcholine, has contributed to our understanding of enzyme kinetics and drug design. Proadifen's unique structural features and its ability to bind to the active site of cholinesterase have also made it a useful tool for investigating the structure and function of this important enzyme.'

Proadifen: An inhibitor of drug metabolism and CYTOCHROME P-450 ENZYME SYSTEM activity. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4910
CHEMBL ID282567
CHEBI ID92811
SCHEMBL ID122630
MeSH IDM0017595

Synonyms (91)

Synonym
2-diethylaminoethyl-2,2-diphenylvalerate
brn 2478573
valeric acid, 2,2-diphenyl-, 2-(diethylamino)ethyl ester
proadifen [inn]
hl 8727
2-diethylaminoethyl propyldiphenylacetate
ccris 7248
ai3-22951
2,2-diphenylpentansaeure-2-diethylaminoethylester
proadifene [inn-french]
av 54315
proadifenum [inn-latin]
proadifeno [inn-spanish]
benzeneacetic acid, alpha-phenyl-alpha-propyl-, 2-(diethylamino)ethyl ester
ethyl aprofen
BRD-K46317332-003-06-1
BRD-K46317332-003-05-3
bctb
acetic acid, propyldiphenyl-, 2-(diethylamino)ethyl ester
2-diethylaminoethyl 2,2-diphenylpentanoate
proadifen
2-(diethylamino)ethyl 2,2-diphenylvalerate hydrochloride
benzeneacetic acid, .alpha.-phenyl-.alpha.-propyl-, 2-(diethylamino)ethyl ester
nsc170997
nsc39690
2-diethylaminoethyl .alpha.,.alpha.-diphenyl valerate hydrochloride
2-(diethylamino)ethyl 2,2-diphenylpentanoate
KBIO1_000737
DIVK1C_000737
SPECTRUM_001487
BSPBIO_000856
PRESTWICK2_000778
IDI1_000737
lopac-p-1061
NCGC00015799-01
NCGC00015799-02
cas-62-68-0
LOPAC0_000906
BPBIO1_000942
PRESTWICK3_000778
BSPBIO_002783
HSCI1_000231
SPECTRUM5_001164
AB00053629
KBIO2_001967
KBIOGR_000675
KBIO2_004535
KBIOSS_001967
KBIO3_002283
KBIO2_007103
SPECTRUM4_000328
SPECTRUM3_001172
SPBIO_002795
PRESTWICK1_000778
SPECTRUM2_000924
PRESTWICK0_000778
SPBIO_000828
NINDS_000737
NCGC00162290-01
302-33-0
STK049476
NCGC00015799-04
CHEMBL282567 ,
2-benzhydryl-pentanoic acid 2-diethylamino-ethyl ester
2,2-diphenyl-pentanoic acid 2-diethylamino-ethyl ester
bdbm50017716
AKOS003658590
a510ca4cbt ,
unii-a510ca4cbt
4-09-00-02566 (beilstein handbook reference)
CCG-204988
NCGC00015799-03
SCHEMBL122630
2-(diethylamino)ethyl-2,2-diphenylvalerate
DTXSID2048452
5171 rp (salt/mix)
proadifen hydrochloride (salt/mix)
SNTQPLDRUZOSDP-UHFFFAOYSA-N
rp 5171 (salt/mix)
2,2-diphenylvaleric acid 2-(diethylamino)ethyl ester
skf-525-a (salt/mix)
nsc-39690 (salt/mix)
2-(diethylamino)ethyl 2,2-diphenylpentanoate #
AB00053629_10
AB00053629_11
CHEBI:92811
SBI-0050881.P003
Q7246819
BRD-K46317332-003-10-3
SDCCGSBI-0050881.P004
NCGC00015799-11

Research Excerpts

Overview

Proadifen (SKF-525A) is a P450 monooxygenase inhibitor. It has potential anti-proliferative activity and the ability to potentiate the toxicity of hypericin-mediated photodynamic therapy and mitoxantrone.

ExcerptReferenceRelevance
"Proadifen (SKF-525A) is a P450 monooxygenase inhibitor with potential anti-proliferative activity and the ability to potentiate the toxicity of hypericin-mediated photodynamic therapy and mitoxantrone via alteration of ABC transport proteins. "( Proadifen sensitizes resistant ovarian adenocarcinoma cells to cisplatin.
Fedoročko, P; Hiľovská, L; Jendželovská, Z; Jendželovský, R; Kovaľ, J; Mikeš, J, 2016
)
3.32
"Proadifen (SKF-525A) is a well-known inhibitor of cytochrome P450 monooxygenases. "( Inhibition of GSK-3β reverses the pro-apoptotic effect of proadifen (SKF-525A) in HT-29 colon adenocarcinoma cells.
Fedoročko, P; Jendželovský, R; Koval, J; Mikeš, J; Papčová, Z; Plšíková, J, 2012
)
2.07

Treatment

Proadifen-treatment and Nx had no significant effect on the duration of the hypotension in control rats or in L-NAME-treated rats. Pretreatment with proadifEN (50 mg/kg, 5 h before ipsapirone), i.e. an inhibitor of trazodone metabolism, caused a greater than 30-fold leftward shift in the dose-response curve.

ExcerptReferenceRelevance
"Proadifen-treatment and Nx had no significant effect on the duration of the hypotension in control rats or in L-NAME-treated rats."( The role of nephrectomy and proadifen in blood pressure homeostasis following an acute kinin-induced hypotension in normotensive rats.
Berg, T; Holte, HR, 1996
)
1.31
"Pretreatment with proadifen (50 mg/kg, 5 h before ipsapirone), i.e."( Are 5-HT1A autoreceptors involved in the inhibitory effect of ipsapirone on cold-elicited thyrotropin secretion?
Baudrie, V; Bluet-Pajot, MT; Broqua, P; Chaouloff, F; Laude, D; Schmidt, B, 1993
)
0.61
"Pretreatment with proadifen (50 mg/kg i.p.), an inhibitor of trazodone metabolism, caused a greater than 30-fold leftward shift in the dose-response curve for both the reinforcement rate and the response rate."( Antidepressant-like effects of trazodone on a behavioral screen are mediated by trazodone, not the metabolite m-chlorophenylpiperazine.
Hand, TH; Li, AA; Marek, GJ; Seiden, LS, 1990
)
0.6

Toxicity

ExcerptReferenceRelevance
"The effect of SKF-525A and phenobarbital on the LD50 values of vinblastine and vincristine suggests that the toxicity of these agents in mice does not arise from a toxic metabolite."( Phenobarbital and SKF-525A on vinblastine and vincristine toxicity in mice.
Fitzgerald, TJ, 1976
)
0.26
"The role of S-oxidation in the toxic bioactivation of alpha-naphthylisothiocyanate (ANIT) was investigated."( Effect of inhibitors of alpha-naphthylisothiocyanate-induced hepatotoxicity on the in vitro metabolism of alpha-naphthylisothiocyanate.
Hanzlik, RP; Traiger, GJ; Vyas, KP, 1985
)
0.27
" It is well established that the pneumotoxicity of MCT depends on its hepatic bioactivation to monocrotaline pyrrole (MCTP) and perhaps other toxic metabolites."( Effect of a mixed function oxidase inducer and inhibitor on monocrotaline pyrrole pneumotoxicity.
Bruner, LH; Carpenter, LJ; Hamlow, P; Roth, RA, 1986
)
0.27
" We have hypothesized these lesions to be related to the adverse hepatic actions of MCT and other PAs."( Modulation of monocrotaline-induced hepatic genotoxicity in rats.
Petry, TW; Sipes, IG, 1987
)
0.27
" These results suggest that the exposure limit for a chemical with a short biological half-life and readily reversible toxic effect may not need to be adjusted for a longer workshift which is in agreement with some of the mathematical models based upon the pharmacokinetics of a toxicant."( The effect of an unusual workshift on chemical toxicity. I. Studies on the exposure of rats and mice to dichloromethane.
Carlson, GP; Kim, YC, 1986
)
0.27
" We assessed the effects of these drugs on the acute toxicity of parathion in rats by measuring the rate of survival at 24 h after the administration of the oral LD50 of parathion to four groups of rats: control and pretreated with the aforementioned drugs."( Cimetidine enhances and phenobarbital decreases parathion toxicity.
Amezcua, JL; Girón, E; Martinez-Tabche, L; Mourelle, M, 1986
)
0.27
" The intraperitoneal LD50 of lobeline sulfate following SKF 525-A (75 mg/kg), phenobarbital (PB), and 3-methylcholanthrene (3-MC) were 18."( Effects of SKF 525-A, phenobarbital and 3-methylcholanthrene on the toxicity of lobeline sulfate.
Kim, HL, 1985
)
0.27
" The present study was undertaken to study the toxic effect of AFB1 on hepatocyte and RNA synthesis, and to assess the influence of the inhibitors on AFB1-induced cytotoxicity and AFB1-inhibited RNA synthesis."( Effect of inhibitors of microsomal enzymes on aflatoxin B1-induced cytotoxicity and inhibition of RNA synthesis in isolated rat hepatocytes.
Ch'ih, JJ; Devlin, TM; Lin, T, 1983
)
0.27
" LC was slightly more toxic to control hepatocytes than SC in the graded response range of 10-160 microM."( Influences of various xenobiotic inducers on cytocidal toxicity of lasiocarpine and senecionine in primary cultures of rat hepatocytes.
Cameron, RC; Farber, E; Hayes, MA; Jago, MV; Roberts, E; Safe, SH, 1984
)
0.27
" The overall results show the necessity of TASO bioactivation by mixed-function monooxygenases for the toxic action to be apparent; at the same time, the findings suggest FADM as the system mainly involved in TASO metabolism."( Role of the microsomal FAD-containing monooxygenase in the liver toxicity of thioacetamide S-oxide.
Chieli, E; Malvaldi, G, 1984
)
0.27
"The possible correlations between embryotoxicity, plasma kinetics of toxic metabolites and covalent binding of metabolites to foetal tissues were studied using two drugs, albendazole and oxfendazole."( A correlation of toxicity of albendazole and oxfendazole with their free metabolites and bound residues.
Benoit, E; Delatour, P; Garnier, F; Longin, C, 1984
)
0.27
" Furthermore, a lack of central nervous system cellular tolerance was demonstrated by the finding that intracerebroventricular LD50 values for propoxyphene in propoxyphene- and water-treated mice were identical to the value derived from naive mice."( Effect of repeated oral propoxyphene administration on analgesia, toxicity and microsomal metabolism in the mouse.
Masten, LW, 1980
)
0.26
" Slices prepared from mice pretreated with phenobarbital (an inducer of P450) potentiated the toxic effects of MPP+."( Protection and potentiation of 1-methyl-4-phenylpyridinium-induced toxicity by cytochrome P450 inhibitors and inducer may be due to the altered uptake of the toxin.
Pai, KS; Ravindranath, V; Sriram, K, 1995
)
0.29
" In exposed mice the liver is the main target for the toxic effects of CYN."( Cylindrospermopsin-induced protein synthesis inhibition and its dissociation from acute toxicity in mouse hepatocytes.
Burcham, PC; Falconer, IR; Froscio, SM; Humpage, AR, 2003
)
0.32
"Some of the more striking expressions of toxicity are the tremors and seizures observed approximately 100 min after exposure of rats to an acutely toxic dose of acrylonitrile (AN)."( Effect of cytochrome P450 inhibitors and anticonvulsants on the acute toxicity of acrylonitrile.
Benz, FW; Nerland, DE, 2005
)
0.33
"Isoline, a major retronecine-type pyrrolizidine alkaloid (PA) from the Chinese medicinal herb Ligularia duciformis, was suggested to be the most toxic known PA."( In vitro metabolism of isoline, a pyrrolizidine alkaloid from Ligularia duciformis, by rodent liver microsomal esterase and enhanced hepatotoxicity by esterase inhibitors.
Akao, T; Hattori, M; Nakamura, N; Sasahara, M; Takagawa, K; Tang, J; Wang, ZT, 2007
)
0.34
" These data demonstrate that the parent forms of leflunomide and A77 1726 are more toxic to hepatocytes than their poorly characterized metabolites, indicating that the metabolic process of leflunomide is a detoxification step rather than an initiating event leading to toxicity."( Hepatic cytochrome P450s attenuate the cytotoxicity induced by leflunomide and its active metabolite A77 1726 in primary cultured rat hepatocytes.
Greenhaw, J; Salminen, WF; Shi, Q; Yang, X, 2011
)
0.37
" These data demonstrate that UA is bio-transformed to less toxic metabolites in rat primary hepatocytes, probably mainly by CYP1A and 3A, but not 2B/2C."( Inhibition of cytochrome P450s enhances (+)-usnic acid cytotoxicity in primary cultured rat hepatocytes.
Greenhaw, J; Salminen, WF; Shi, Q, 2014
)
0.4

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic observations were compared with the time course of drug-induced hypothermia in cold-room acclimatized rats."( Pharmacokinetics and pharmacodynamics of bromocriptine in the rat.
Bhuta, SI; Schran, HF; Tse, FL,
)
0.13
" The feasibility of the brain microdialysis method for direct measurement and pharmacokinetic study of imipramine (Imip) and its metabolite desipramine (DMI) was investigated in the rat brain."( Measurement and pharmacokinetic analysis of imipramine and its metabolite by brain microdialysis.
Ishikawa, K; Sato, Y; Shibanoki, S; Sugahara, M, 1994
)
0.29
" However, the pharmacokinetic parameters of parathion were not significantly different after pretreatment with other enzyme inducers compared with respective control rats."( Effects of enzyme inducers or inhibitors on the pharmacokinetics of intravenous parathion in rats.
Hurh, E; Kim, S; Kim, Y; Lee, A; Lee, E; Lee, M, 2000
)
0.31
") was injected to rats for a pharmacokinetic study using microdialysis coupled with HPLC."( Pharmacokinetics of baicalin in rats and its interactions with cyclosporin A, quinidine and SKF-525A: a microdialysis study.
Tsai, PL; Tsai, TH, 2004
)
0.32
"These findings could help explain possible pharmacokinetic changes of furosemide in various rat disease models (where CYP2C11, 2E1, 3A1 and/or CYP3A2 are altered) and drug-drug interactions between furosemide and other drugs (mainly metabolized via CYP2C11, 2E1, 3A1 and/or 3A2)."( Effects of cytochrome P450 inducers and inhibitors on the pharmacokinetics of intravenous furosemide in rats: involvement of CYP2C11, 2E1, 3A1 and 3A2 in furosemide metabolism.
Choi, YH; Lee, JH; Lee, MG; Lee, U; Yang, KH, 2009
)
0.35
"The area under concentration curve (AUC) was significantly increased; however, the clearance (Cl) was significantly decreased in the liver I/R rats."( Isolation of gentiopicroside from Gentianae Radix and its pharmacokinetics on liver ischemia/reperfusion rats.
Chang-Liao, WL; Chien, CF; Lin, LC; Tsai, TH, 2012
)
0.38

Compound-Compound Interactions

ExcerptReferenceRelevance
"Antitumor activity and lethality of cyclophosphamide alone and in combination with several drugs were investigated in male ddY mice."( [Drug interaction on antitumor drugs I. Antitumor activity of cyclophosphamide in mice consecutively administered aminopyrine, chlorpromazine, or morphine (author's transl)].
Saitoh, M; Sasaki, K; Takayanagi, G, 1979
)
0.26

Bioavailability

ExcerptReferenceRelevance
"Ten commercial products containing 65 mg propoxyphene hydrochloride have been evaluated for their relative bioavailability in human subjects in a complete crossover study."( Propoxyphene bioavailability: an evaluation of ten products.
Melikian, AP; Meyer, MC; Slywka, GW; Whyatt, PL,
)
0.13
" The results indicated that oral doses of bromocriptine were rapidly, though incompletely (32-40 per cent), absorbed, but underwent extensive first-pass metabolism, resulting in an absolute bioavailability of only 6 per cent."( Pharmacokinetics and pharmacodynamics of bromocriptine in the rat.
Bhuta, SI; Schran, HF; Tse, FL,
)
0.13
"87 mmol/kg) of 2-14C-MAN or 2-14C-AN to male F344 rats, both chemicals were well absorbed from the GI tract and distributed to all major tissues."( Comparative metabolism and disposition of acrylonitrile and methacrylonitrile in rats.
Ahmed, AE; Burka, LT; Ghanayem, BI; Sanchez, IM, 1994
)
0.29
"Biotransformation in the intestine may influence the bioavailability and toxicity of ingested xenobiotics."( Properties and regional expression of a CYP3A-like protein in channel catfish intestine.
Celander, MC; James, MO; Lou, Z; Rowland-Faux, L, 2005
)
0.33
" The oral bioavailability of GPS was 10."( Isolation of gentiopicroside from Gentianae Radix and its pharmacokinetics on liver ischemia/reperfusion rats.
Chang-Liao, WL; Chien, CF; Lin, LC; Tsai, TH, 2012
)
0.38

Dosage Studied

ExcerptRelevanceReference
" In conjunction with this fact, the poor availability of CF3-PER in the central compartment and extrahepatic tissues following oral dosage points to a pronounced first-pass effect."( Metabolism and disposition of trifluoperazine in the rat. II. Kinetics after oral and intravenous administration in acutely and chronically treated animals.
Schmalzing, G,
)
0.13
" In contrast with the membrane fragments of Electrophorus, however, those of Torpedo give dose-response curves of in vitro excitation that shift towards higher concentration of the agonists by one to two orders of magnitude compared with the actual binding curves of agonists to the receptor sites."( The mode of action of the nicotinic cholinergic receptor protein in the postsynaptic membrane.
Sugiyama, H, 1978
)
0.26
"Evidence of selective inhibition, differences in dose-response relationships, and cross-tachyphylaxis studies suggest that separate receptors and/or mechanisms may be involved in responses to angiotensin (Ang), [Sar1]Ang II, and Ang III (= des-Asp1-Ang II)."( Demonstration of different contractile mechanisms for angiotensin II and des-Asp1-angiotensin II in rabbit aortic strips.
Ackerly, JA; Moore, AF; Peach, MJ, 1977
)
0.26
" Cocaine (2 x 10(-6) M and 10(-5) M) produced 2 and 7 fold shifts to the left of the dose-response curve to (-)-noradrenaline recorded isotonically in isolated splenic capsular strips of the cat."( Investigation of the role of calcium in the supersensitivity produced by cocaine in cat spleen strips.
Summers, RJ; Tillman, J, 1979
)
0.26
" PC potentiated NA action, and its methobromide (MeBr) derivative potentiated both NA and K+ action and also, like PC, partially shifted to the left the dose-response curve to Ca2+ in NA-depolarizing Ca-free Tyrode's."( Calcium antagonists and contractile responses in rat vas deferens and guinea pig ileal smooth muscle.
Swamy, VC; Triggle, CR; Triggle, DJ, 1979
)
0.26
" Furthermore, usual increase in the activity of drug biotransformation enzymes seen after phenobarbital treatment appears to decrease in rats dosed with this funaicide."( Toxicologic studies of N-trichloromethylthio-4-cyclohexene-1,2-dicarboximide (captan): its metabolism by rat liver drug-metabolizing enzyme system.
Dalvi, RR; Peeples, A, 1978
)
0.26
" Dose-response curves with and without phenobarbital pretreatment showed a constant 90% (1-log) reduction in the toxicity of cyclophosphamide to leukemic colony-forming units, whereas enzyme induction had no effect on the toxicity of the drug to normal bone marrow colony-forming units."( The effect of phenobarbital on cyclophosphamide antitumor activity.
Alberts, DS; van Daalen Wetters, T, 1976
)
0.26
" Rats dosed intraperitoneally or orally with ara-DMAP excreted unchanged ara-DMAP and one major metabolite, 6-methylaminopurine arabinoside (ara-MAP), in the urine."( Metabolism and pharmacokinetics of the anti-varicella-zoster virus agent 6-dimethylaminopurine arabinoside.
Koszalka, GW; Lambe, CU; Nelson, DJ; Resetar, A; Spector, T, 1992
)
0.28
" The surface AChRs exhibit pharmacological properties identical to those obtained for BC3H-1 cells, including the association and dissociation rates of alpha-bungarotoxin, a low affinity and cooperative instantaneous dose-response curve, cooperative steady state agonist binding and desensitization, cooperative enhancement of agonist binding affinity by local anesthetics, and distinct affinities for curariform antagonists."( Stable expression of the mouse nicotinic acetylcholine receptor in mouse fibroblasts. Comparison of receptors in native and transfected cells.
Claudio, T; Sine, SM, 1991
)
0.28
"), an inhibitor of trazodone metabolism, caused a greater than 30-fold leftward shift in the dose-response curve for both the reinforcement rate and the response rate."( Antidepressant-like effects of trazodone on a behavioral screen are mediated by trazodone, not the metabolite m-chlorophenylpiperazine.
Hand, TH; Li, AA; Marek, GJ; Seiden, LS, 1990
)
0.28
" Cyclooxygenase inhibition with indomethacin displaced the dose-response curve to AA to the right but did not prevent the relaxant effects of the fatty acid."( Arachidonic acid-induced endothelial-dependent relaxations of canine coronary arteries: contribution of a cytochrome P-450-dependent pathway.
Abraham, NG; Mullane, KM; Pinto, A, 1987
)
0.27
"To study the effects of SKF-525A, an inhibitor of cytochrome P-450, and of sodium phenobarbital (PB), a drug-metabolizing enzyme inducer, on the teratogenicity of thiabendazole (TBZ), pregnant mice were given ip either a single dose of 40 mg SKF-525A/kg 1 hr before oral dosing with 250 or 500 mg TBZ/kg or a dose of 75 mg PB/kg/day on three consecutive days before oral administration of a dose of 500 or 1000 mg TBZ/kg."( Effects of pretreatment with SKF-525A or sodium phenobarbital on thiabendazole-induced teratogenicity in ICR mice.
Imamichi, T; Ogata, A; Sasaki, M; Suzuki, K; Yoneyama, M, 1987
)
0.27
" Differences in dose-response curves for certain mutagens using liver and intestinal microsomes are discussed in relation to variation in metabolism of promutagens."( Characterization of a microsomal fraction from rat small intestine for metabolic activation of some promutagens.
Combes, RD; Walters, JM, 1985
)
0.27
" Dose-response curves in benzene-treated mice were much steeper with 3-MCA induction than without."( Modifications in the myeloclastogenic effect of benzene in mice with toluene, phenobarbital, 3-methylcholanthrene, Aroclor 1254 and SKF-525A.
Gad-El-Karim, MM; Harper, BL; Legator, MS, 1984
)
0.27
" MMI and ETU were dosed simultaneously, one hour after dosing with SKF."( Effects of pretreatment with SKF-525A, N-Methyl-2-thioimidazole, sodium phenobarbital, or methyl cholanthrene on ethylenethiourea-induced teratogenicity in rats.
Iverson, F; Khera, KS, 1981
)
0.26
" The effects of cytochrome P-450 inhibitor [2-dimethylaminoethyl-2,2-diphenyl-n-pentanoate (SKF-525A) and metyrapone] on the response of rabbit aortic rings to GTN was determined by recording cumulative GTN dose-response curves in the presence of either or both inhibitors."( Lack of evidence for the involvement of cytochrome P-450 or other hemoproteins in metabolic activation of glyceryl trinitrate in rabbit aorta.
Brien, JF; Liu, Z; Marks, GS; McLaughlin, BE; Nakatsu, K, 1993
)
0.29
" The aorta, which is representative of the connective tissue, retained considerable radioactivity after dosing for both the imidazoles."( Retention mechanism of imidazoles in connective tissue. I. Binding to elastin.
Akimoto, M; Awazu, S; Fukushima, K; Ohta, K; Suwa, T; Yamaguchi, JI, 1996
)
0.29
" The nonspecific cytochrome P450 inhibitor SKF-525A (10 microM) exhibited a partial dose-response inhibition (maximum 41% of complete reaction mixture) of N'HA formation, but did not alter NHA formation."( Rat liver cytochrome P450 metabolism of N-acetylbenzidine and N,N'-diacetylbenzidine.
Davis, BB; Lakshmi, VM; Zenser, TV, 1997
)
0.3
" We compared cumulative CCK dose-response relationship in control cells and in cells where P450 had been induced by prior injection of animals with beta-naphthoflavone."( Pharmacological evaluation of the role of cytochrome P450 in intracellular calcium signalling in rat pancreatic acinar cells.
Bruce, JI; Elliott, AC, 2000
)
0.31
" The results indicate that berberine displays a linear pharmacokinetic phenomenon in the dosage range from 10 to 20 mg kg(-1), since a proportional increase in the area under the concentration-time curve (AUC) of berberine was observed in this dosage range."( Hepatobiliary excretion of berberine.
Tsai, PL; Tsai, TH, 2004
)
0.32
" Rats were pretreated with PB (75 mg/kg for 4 days) prior to itraconazole or fluconazole dosing (20 and 200 mg/kg for 4 days)."( Involvement of phenobarbital and SKF 525A in the hepatotoxicity of antifungal drugs itraconazole and fluconazole in rats.
Ahmad Bustamam, A; Hasiah, AH; Israf, DA; Khairi, HM; Somchit, N; Sulaiman, MR; Wong, CW; Zuraini, A, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
diarylmethaneAny compound containing two aryl groups connected by a single C atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (39)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
phosphopantetheinyl transferaseBacillus subtilisPotency39.81070.141337.9142100.0000AID1490
ATAD5 protein, partialHomo sapiens (human)Potency19.72990.004110.890331.5287AID493106; AID493107
USP1 protein, partialHomo sapiens (human)Potency35.48130.031637.5844354.8130AID504865
NFKB1 protein, partialHomo sapiens (human)Potency1.00000.02827.055915.8489AID895; AID928
thyroid stimulating hormone receptorHomo sapiens (human)Potency25.11890.001318.074339.8107AID926
arylsulfatase AHomo sapiens (human)Potency8.49211.069113.955137.9330AID720538
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency0.03950.00207.533739.8107AID891
cytochrome P450 2C19 precursorHomo sapiens (human)Potency5.96220.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency12.58930.00636.904339.8107AID883
chromobox protein homolog 1Homo sapiens (human)Potency39.81070.006026.168889.1251AID488953
atrial natriuretic peptide receptor 2 precursorHomo sapiens (human)Potency10.39920.00669.809418.4927AID1347050
ras-related protein Rab-9AHomo sapiens (human)Potency91.99970.00022.621531.4954AID485297
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency14.68920.00378.618923.2809AID2668
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency1.49770.031610.279239.8107AID884; AID885
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency5.83340.00106.000935.4813AID943; AID944
lamin isoform A-delta10Homo sapiens (human)Potency0.50120.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency1.49771.000012.224831.6228AID885
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency11.29470.316212.765731.6228AID881
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency1.49771.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency1.49771.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency1.49771.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency1.49771.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency1.49771.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency1.49771.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency1.49771.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency1.49771.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency1.49771.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency1.49771.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency11.84950.00638.235039.8107AID881; AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency1.49771.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency1.49771.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency1.49771.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency1.49771.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency1.49771.000012.224831.6228AID885
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency37.93300.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)13.19000.11007.190310.0000AID1449628
Aldehyde oxidaseHomo sapiens (human)IC50 (µMol)200.00000.00230.63203.3000AID547838
Sigma non-opioid intracellular receptor 1Homo sapiens (human)IC50 (µMol)1.58490.00030.70285.3660AID203852
Sigma non-opioid intracellular receptor 1Homo sapiens (human)Ki0.01700.00000.490110.0000AID204635
Aldehyde oxidase 1 Rattus norvegicus (Norway rat)IC50 (µMol)1.10000.19001.90606.4000AID547840
Aldehyde oxidase 1 Rattus norvegicus (Norway rat)Ki0.30000.03001.11003.0000AID547840
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (48)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
lipid metabolic processAldehyde oxidaseHomo sapiens (human)
xenobiotic metabolic processAldehyde oxidaseHomo sapiens (human)
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (24)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
aldehyde oxidase activityAldehyde oxidaseHomo sapiens (human)
iron ion bindingAldehyde oxidaseHomo sapiens (human)
identical protein bindingAldehyde oxidaseHomo sapiens (human)
protein homodimerization activityAldehyde oxidaseHomo sapiens (human)
molybdopterin cofactor bindingAldehyde oxidaseHomo sapiens (human)
flavin adenine dinucleotide bindingAldehyde oxidaseHomo sapiens (human)
NAD bindingAldehyde oxidaseHomo sapiens (human)
2 iron, 2 sulfur cluster bindingAldehyde oxidaseHomo sapiens (human)
FAD bindingAldehyde oxidaseHomo sapiens (human)
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (28)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
cytosolAldehyde oxidaseHomo sapiens (human)
extracellular exosomeAldehyde oxidaseHomo sapiens (human)
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (61)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1725260Cytotoxicity against human HepaRG cells infected with HBV assessed as reduction in cell viability at 50 uM treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days then follow2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID205267Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID1725263Inhibition of CYP3A4 in HBV-infected human primary hepatocytes at 5 to 100 uM using luciferin-IPA as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days then fo2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID1725295Inhibition of CYP3A4 in HBV-infected human HepaRG cells at 5 to 100 uM using luciferin-IPA as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days then followed 2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID327555Displacement of [131I]IMTO from CYP450c 11 in Wistar rat adrenal membrane2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
New selective inhibitors of steroid 11beta-hydroxylation in the adrenal cortex. Synthesis and structure-activity relationship of potent etomidate analogues.
AID1725299Inhibition of CYP1A2 in HBV-infected human HepaRG cells at 5 to 100 uM using luciferin-1A2 as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days then followed 2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID203852The compound was tested for affinity towards sigma-3 receptor1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
Conformational analysis, pharmacophore identification, and comparative molecular field analysis of ligands for the neuromodulatory sigma 3 receptor.
AID1725286Inhibition of CYP1A2 in HBV-infected human HepaRG cells at 50 uM using luciferin-1A2 as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days by P450-Glo chemilum2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID1725281Inhibition of CYP3A4 in HBV-infected human HepaRG cells at 50 uM using luciferin-IPA as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days then followed by tre2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID1725284Inhibition of CYP2C9 in HBV-infected human HepaRG cells at 50 uM using luciferin-H as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days by P450-Glo chemilumin2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID1725302Cytotoxicity against human primary hepatocytes infected with HBV assessed as reduction in cell viability at 50 uM treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days then2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID204767Binding affinity of compound was measured towards Sigma receptor type 2 by using [3H]ditolylguanidine as radioligand2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Thioxanthene-derived analogs as sigma(1) receptor ligands.
AID1725269Inhibition of CYP3A4 in HBV-infected human HepaRG cells at 50 uM using luciferin-IPA as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days then followed by tre2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID1725292Cytotoxicity against human HepaRG cells infected with HBV assessed as reduction in cell viability at 5 to 100 uM treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days then 2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID1725270Inhibition of CYP3A4 in HBV-infected human HepaRG cells at 50 uM using luciferin-IPA as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days in presence of 10 mM2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID1725278Inhibition of CYP1A2 in HBV-infected human HepaRG cells at 50 uM using luciferin-1A2 as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days in presence of 10 mM2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID205268Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID1725282Inhibition of CYP3A4 in HBV-infected human HepaRG cells at 50 uM using luciferin-IPA as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days by P450-Glo chemilum2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID547838Inhibition of human aldehyde oxidase2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Aldehyde oxidase: an enzyme of emerging importance in drug discovery.
AID1725304Antiviral activity against Hepatitis B virus infected in human primary hepatocytes assessed as reduction in HbsAg secretion level at 25 uM treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further 2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID1725273Inhibition of CYP2C9 in HBV-infected human HepaRG cells at 50 uM using luciferin-H as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days then followed by treat2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID1725283Inhibition of CYP2C9 in HBV-infected human HepaRG cells at 50 uM using luciferin-H as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days then followed by treat2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID547840Inhibition of rat aldehyde oxidase2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Aldehyde oxidase: an enzyme of emerging importance in drug discovery.
AID547841Inhibition of guinea pig aldehyde oxidase2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Aldehyde oxidase: an enzyme of emerging importance in drug discovery.
AID1725274Inhibition of CYP2C9 in HBV-infected human HepaRG cells at 50 uM using luciferin-H as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days in presence of 10 mM A2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID269964Photolabeling of Torpedo californica alpha nAChR in presence of agonist relative to in absence of agonist2006Journal of medicinal chemistry, Aug-10, Volume: 49, Issue:16
Synthesis of trifluoromethylaryl diazirine and benzophenone derivatives of etomidate that are potent general anesthetics and effective photolabels for probing sites on ligand-gated ion channels.
AID1725258Antiviral activity against Hepatitis B virus infected in human primary hepatocytes assessed as reduction in HbsAg secretion level at 50 uM treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further 2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1725265Inhibition of CYP2C9 in HBV-infected human primary hepatocytes at 5 to 100 uM using luciferin-H as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days then foll2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID1725285Inhibition of CYP1A2 in HBV-infected human HepaRG cells at 50 uM using luciferin-1A2 as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days then followed by tre2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID1725262Antiviral activity against Hepatitis B virus infected in human HepaRG cells assessed as reduction in HbsAg secretion level at 50 uM treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubat2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID234548Selectivity for sigma 2 compared to sigma 1 receptor2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Thioxanthene-derived analogs as sigma(1) receptor ligands.
AID1725267Inhibition of CYP1A2 in HBV-infected human primary hepatocytes cells at 5 to 100 uM using luciferin-1A2 as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days t2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID289115Inhibition of CYP450-mediated tangeretin demethylation in Aspergillus niger ATCC 9142 assessed as relative activity at 0.5 mM2007Journal of natural products, Jun, Volume: 70, Issue:6
Biotransformation of polymethoxylated flavonoids: access to their 4'-O-demethylated metabolites.
AID1725277Inhibition of CYP1A2 in HBV-infected human HepaRG cells at 50 uM using luciferin-1A2 as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days then followed by tre2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID38615Relative binding affinity (RBA) against AEBS (Antiestrogen binding site) in rat liver1992Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8
Synthesis of 2-(p-chlorobenzyl)-3-aryl-6-methoxybenzofurans as selective ligands for antiestrogen-binding sites. Effects on cell proliferation and cholesterol synthesis.
AID1725297Inhibition of CYP2C9 in HBV-infected human HepaRG cells at 5 to 100 uM using luciferin-H as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days then followed by2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
AID204635Binding affinity for Sigma receptor type 1,using [3H](+)-pentazocine as radioligand2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Thioxanthene-derived analogs as sigma(1) receptor ligands.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,386)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901063 (76.70)18.7374
1990's168 (12.12)18.2507
2000's113 (8.15)29.6817
2010's35 (2.53)24.3611
2020's7 (0.51)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.09 (24.57)
Research Supply Index7.30 (2.92)
Research Growth Index4.06 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews24 (1.62%)6.00%
Case Studies1 (0.07%)4.05%
Observational0 (0.00%)0.25%
Other1,456 (98.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]